Please note: You’ll get an immediate assessment when you request PBS authorities online.
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with daratumumab under the National Health Act 1953, section 85 for patients with newly diagnosed systemic light chain amyloidosis.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing daratumumab.
Treatment specifics
To be eligible for PBS-subsidised treatment with daratumumab, patients must be treated by a haematologist (this does not exclude treatment via a multidisciplinary team, but the PBS authority application must be written by the treating haematologist).
Authority applications
Applying for initial treatment
Applications for initial authority approval to prescribe PBS-subsidised daratumumab to treat newly diagnosed systemic light chain amyloidosis can be made either in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS authority approvals.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed systemic light chain amyloidosis newly diagnosed - daratumumab - initial authority application form
- relevant attachments.
Applying for continuing treatment
Applications for continuing authority approval to prescribe PBS-subsided daratumumab to treat newly diagnosed systemic light chain amyloidosis can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS authority approvals line.
More information
Call the PBS authority approvals line for more information.